Fig. 1. Elevated MEDAG expression indicates adverse clinicopathological characteristics and poor survival in breast cancer patients.

A–C MEDAG expression in breast cancer samples and normal breast tissues was detected by an immunohistochemistry (IHC) assay. Quantitative analysis is shown in (A). Representative images are shown in (B, C) (magnification 200x). D mRNA levels of MEDAG in tumor tissues and corresponding normal tissues. E, F Percentages of human breast cancer samples with a high expression of MEDAG with a vascular invasion status and lymph node metastasis (χ² test). G–I High MEDAG expression is correlated with a poorer disease-free survival in all breast cancer patients, ER+/PR+ patients and ER−/PR− patients (log-rank test).